Business / Finance

RSS

Catamaran acquires Healthcare Solutions for $405 million

Catamaran Corporation, a leading provider of pharmacy benefit management (PBM) services and technology solutions, announced today the completion, effective as of April 8, 2015, of its previously disclosed acquisition of Healthcare Solutions, for a purchase price of $405 million in cash, subject to certain customary post-closing adjustments. The purchase price was funded from Catamaran's existing cash balance.

9 Apr 2015

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its SATx™ platform...

9 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

Livongo Health secures $20 million in Series B funding

Livongo Health, a consumer digital health company that is empowering people with chronic diseases to live better, announced today that it has secured $20 million in Series B funding from investors including Kleiner Perkins Caufield & Byers (KPCB), DFJ and previous investor General Catalyst.

7 Apr 2015

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also announced it recently raised an additional $4 million in equity financing from inside investors.

7 Apr 2015

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.

7 Apr 2015

DreaMed Diabetes and Medtronic enter strategic collaboration

DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed’s MD-Logic Artificial Pancreas algorithm in Medtronic’s insulin pumps.

From Medtronic 7 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

High Throughput ChIP Sequencing

Chromatrap®, a business unit of Porvair Sciences, has announced a major product launch at the European Human Genetics Conference (Glasgow, UK) and the Festival of Genomics (Boston, USA) on the 6th June 2015 and 22nd-24th June 2015 respectively

From Chromatrap® - Porvair Sciences Ltd 6 Apr 2015

Natera raises $55.5 million in funding led by Sofinnova Ventures

Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures. This financing round also includes participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors.

From Natera 6 Apr 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Radlink, DePuy Synthes sign exclusive worldwide sales agency agreement

Radlink, Inc., an emerging global leader in advanced medical imaging technology, announced today that it has signed an exclusive worldwide sales agency agreement with Johnson & Johnson subsidiary DePuy Synthes Companies. The contractual partnership provides for the exclusive worldwide distribution of Radlink's advanced imaging products, including the revolutionary Galileo Positioning System (GPS) featuring Surgeon's Checklist software, through DePuy Synthes Companies' sales representatives worldwide.

6 Apr 2015

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 618 NW Loop 410 Suite 101 San Antonio, Texas.

3 Apr 2015

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon, formerly BSD Medical. This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.

3 Apr 2015

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has increased its global capacity for Active Pharmaceutical Ingredient (API) Manufacture due to increased demand for API, and for its integrated and comprehensive candidate-to-IND development solution.

3 Apr 2015

Quest Diagnostics grants Supplier Excellence Awards to five companies

Quest Diagnostics, the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2015 Supplier Forum.

From Quest Diagnostics 2 Apr 2015

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

ImmunoClin Corporation, a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.

2 Apr 2015

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics, Inc. today announced the expansion of its companion diagnostic collaboration with AstraZeneca. Under the terms of the expanded agreement, Myriad’s BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib).

2 Apr 2015

Business / Finance

Catamaran acquires Healthcare Solutions for $405 million

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Livongo Health secures $20 million in Series B funding

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Nabriva Therapeutics completes $120 million Series B financing

DreaMed Diabetes and Medtronic enter strategic collaboration

MabVax closes $11.6 million in private placement

High Throughput ChIP Sequencing

Natera raises $55.5 million in funding led by Sofinnova Ventures

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Radlink, DePuy Synthes sign exclusive worldwide sales agency agreement

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Quest Diagnostics grants Supplier Excellence Awards to five companies

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News